4basebio

Based in the heart of the Cambridge UK biotech ecosystem, we are pioneering a paradigm shift: the transition from legacy bacterial-based manufacturing to high-performance, synthetic enzymatic DNA synthesis. Our mission is to empower pharma and biotech innovators with synthetic, cell-free DNA that eliminates risks and streamlines the path from preclinical development to commercialization.

At 4basebio, we don’t just manufacture DNA; we engineer it for the future. Our proprietary enzymatic synthesis platform bypasses the “bottleneck” of traditional DNA manufacturing. By moving away from traditional cell-based, bacterial-fermentation systems, we offer a unique approach to critical starting material. The advantages of synthetic DNA are as follows:

• Unrivaled purity: We eliminate the risks of bacterial contaminants and antibiotic-resistance genes, ensuring a safer profile for clinical applications.
• Scalability at speed: Our enzymatic process transforms timelines, moving from design to GMP-grade DNA and mRNA in a fraction of the time required by pDNA.
• Precision engineering: We create application-specific DNA constructs tailored for the precise needs of gene editing (CRISPR), mRNA production, viral vector, and DNA vaccines.

Learn more at 4basebio.com